Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Liu Huang Zhike Granules
- Development stage
- Unknown
- Lead developer
- Guangdong Kaizhong Biotechnology
- Administration
- Oral
01
Overview
Liu Huang Zhike Granules is a traditional Chinese medicine (TCM) formulation developed by Guangdong Kaizhong Biotechnology for the treatment of type 2 diabetes mellitus. It is specifically indicated for patients exhibiting the Qi and Yin deficiency pattern, a common diagnostic classification in TCM for diabetic patients. The drug is currently being evaluated in a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial in China. The study assesses the efficacy and safety of the granules as a 24-week monotherapy in patients who have failed to achieve adequate glycemic control through diet and exercise alone.
Beyond the preview
Go deeper on Liu Huang Zhike Granules.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Liu Huang Zhike Granules.